Breast, Phase I
A Phase 1 Study of HLD-0117 in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer (MBC)
Volunteers
Health Professionals
What is the purpose of this trial?
Assessment of the safety and efficacy of HLD-0117 as monotherapy in patients with estrogen receptor positive (ER+) metastatic breast cancer (MBC) or locally advanced breast cancer that have progressed on prior systemic therapies.
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Avery Marzulla-Dulfer, PA
- Eric Winer, MD
- Gineesha Abraham, APRN
- Ian Krop, MD, PhD
- Jing Du, MD, PhD, MHS
- Karishma Mehra, MBBS
- Katelyn Scott, APRN
- Kathryn Mason, APRN
- Lajos Pusztai, MD, DPhil
- Maryam Lustberg, MD, MPH
- Melissa Gambaccini, APRN, AOCNP, FNP-C
- Michael DiGiovanna, MD, PhD
- Michelle Corso, APRN
- Nicole Casasanta, MD
- Rachel Iudiciani
- Sarah Elizabeth Schellhorn, MD
- Last Updated10/04/2026
- Study IRB#2000042301